| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
WAY-169916 is a pathway-selective inhibitor of the estrogen receptor (ER). It acts by inhibiting NF-κB transcriptional activity while being devoid of conventional estrogenic activity. This unique mechanism allows the compound to modulate inflammatory pathways through NF-κB inhibition without the typical hormonal effects associated with estrogen receptor modulation. The compound exhibits bioactivities related to the inhibition and modulation of gene expression in liver cells and estrogen receptor pathways.
|
|---|---|
| ln Vitro |
WAY-169916 exhibits potent anti-inflammatory activity. In preclinical studies, it has demonstrated efficacy in the HLA-B27 transgenic rat model of inflammatory bowel disease. The compound also inhibits nuclear factor-kappa B transcriptional activity in models of rheumatoid arthritis. Preclinical studies suggest that WAY-169916 has potential therapeutic applications in cancer, fibrosis, and inflammatory diseases, offering a novel approach to target the remodeling of the extracellular matrix in various pathological conditions.
|
| ln Vivo |
WAY-169916 has demonstrated in vivo anti-inflammatory activity in animal models. It has been shown to be effective in the HLA-B27 transgenic rat model of inflammatory bowel disease. The compound also inhibits NF-κB transcriptional activity in models of rheumatoid arthritis. These in vivo findings support the compound's potential for treating inflammatory and autoimmune conditions. The compound's pathway-selective mechanism, targeting NF-κB without conventional estrogenic activity, contributes to its anti-inflammatory effects in vivo.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for WAY-169916 would typically involve assessing its binding affinity to the estrogen receptor (ER) using radioligand binding assays. The compound's ability to inhibit NF-κB transcriptional activity can be evaluated using reporter gene assays in cell-based systems. These assays measure the compound's potency in modulating NF-κB-mediated gene expression without conventional estrogenic activity.
|
| Cell Assay |
Cellular assays for WAY-169916 involve treating cells with the compound and measuring its effects on NF-κB transcriptional activity. Reporter gene assays are commonly used to evaluate the compound's ability to inhibit NF-κB-mediated gene expression. The compound's anti-inflammatory effects can be assessed in various cell types, including immune cells and liver cells. Its pathway-selective modulation of the estrogen receptor without conventional estrogenic activity can also be evaluated.
|
| Animal Protocol |
In vivo animal model protocols for WAY-169916 involve its administration to animal models of inflammatory diseases. The compound has been studied in the HLA-B27 transgenic rat model of inflammatory bowel disease. It has also been evaluated in models of rheumatoid arthritis. Preclinical studies suggest potential applications in cancer and fibrosis models as well. Dosing regimens and administration routes would be determined based on the specific disease model being studied.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for WAY-169916 is not extensively detailed in the available literature. As a small molecule inhibitor with a molecular weight of 334.29 g/mol, the compound would be expected to have favorable oral bioavailability. It is soluble in DMSO at approximately 125 mg/mL (~373.93 mM). The compound is supplied as a white to off-white solid powder and should be stored at -20°C for long-term stability.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for WAY-169916 is not extensively detailed in the available literature. As a research compound, its safety profile would be evaluated in standard preclinical toxicology studies. The compound is intended for research use only and not for human therapeutic applications. Preclinical studies suggest a favorable safety profile, but comprehensive toxicology data would be required for clinical development.
|
| References | |
| Additional Infomation |
WAY-169916 (CAS# 669764-18-5) is a pathway-selective ligand for the estrogen receptor that acts by inhibiting NF-κB transcriptional activity. It has a molecular weight of 334.29 g/mol and a molecular formula of C17H13F3N2O2. The compound exhibits anti-inflammatory activity and has potential therapeutic applications in cancer, fibrosis, and inflammatory diseases. It is supplied as a white to off-white solid powder and is intended for research use only.
|
| Molecular Formula |
C17H13F3N2O2
|
|---|---|
| Molecular Weight |
334.29
|
| Exact Mass |
334.093
|
| Elemental Analysis |
C, 61.08; H, 3.92; F, 17.05; N, 8.38; O, 9.57
|
| CAS # |
669764-18-5
|
| PubChem CID |
135461982
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.186
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
24
|
| Complexity |
460
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C=CCN1C2=C(C=CC=C2C(F)(F)F)C(=N1)C3=C(C=C(C=C3)O)O
|
| InChi Key |
ZDUDMCQPFKPISO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H13F3N2O2/c1-2-8-22-16-12(4-3-5-13(16)17(18,19)20)15(21-22)11-7-6-10(23)9-14(11)24/h2-7,9,23-24H,1,8H2
|
| Chemical Name |
4-[1-prop-2-enyl-7-(trifluoromethyl)indazol-3-yl]benzene-1,3-diol
|
| Synonyms |
WAY169916; WAY 169916; WAY-169916
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~373.93 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9914 mL | 14.9571 mL | 29.9141 mL | |
| 5 mM | 0.5983 mL | 2.9914 mL | 5.9828 mL | |
| 10 mM | 0.2991 mL | 1.4957 mL | 2.9914 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
